In addition, anti-CCN2 therapy is in phase 2 or 3 clinical trials in other diseases, including Duchenne muscular dystrophy (NCT02606136), idiopathic pulmonary fibrosis (NCT03955146), and pancreatic adenocarcinoma (NCT04229004). Here, CCN2 is linked to pancreatic adenocarcinoma.